Novo Nordisk A/S (NYSE:NVO) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Novo Nordisk A/S (NYSE:NVO) have received a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $145.25.

NVO has been the subject of a number of analyst reports. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NVO. Natixis Advisors LLC increased its position in shares of Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the last quarter. Norman Fields Gottscho Capital Management LLC boosted its holdings in Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after purchasing an additional 19,870 shares in the last quarter. Bryn Mawr Capital Management LLC increased its stake in Novo Nordisk A/S by 358.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock valued at $3,346,000 after purchasing an additional 30,420 shares during the last quarter. Versant Capital Management Inc purchased a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $86,000. Finally, Talbot Financial LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $4,066,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 1.4 %

Shares of NYSE:NVO opened at $89.42 on Thursday. The business’s 50 day moving average price is $84.84 and its 200-day moving average price is $106.18. Novo Nordisk A/S has a 1 year low of $77.82 and a 1 year high of $148.15. The firm has a market capitalization of $401.28 billion, a price-to-earnings ratio of 27.18, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.